MoonLake Immunotherapeutics
MLTX10.630USD
+0.340+3.30%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
677.18MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über MoonLake Immunotherapeutics Unternehmen
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics Informationen
BörsenkürzelMLTX
Name des UnternehmensMoonLake Immunotherapeutics
IPO-datumOct 20, 2020
CEODr. Jorge Santos Da Silva
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeOct 20
AddresseDorfstrasse 29
StadtZUG
BörseNASDAQ Capital Market Consolidated
LandSwitzerland
Postleitzahl6300
Telefon41415108022
Websitehttps://moonlaketx.com/
BörsenkürzelMLTX
IPO-datumOct 20, 2020
CEODr. Jorge Santos Da Silva
Führungskräfte von MoonLake Immunotherapeutics
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
3.13M
+1.59%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
3.08M
--
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Nov 4
Aktualisiert: Tue, Nov 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
Andere
50.37%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
27.67%
Fidelity Management & Research Company LLC
7.44%
Avoro Capital Advisors LLC
5.81%
Reich (Kristian)
4.38%
Santos da Silva (Jorge)
4.31%
Andere
50.37%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
41.51%
Investment Advisor
20.11%
Investment Advisor/Hedge Fund
17.19%
Individual Investor
11.03%
Research Firm
2.11%
Venture Capital
1.30%
Bank and Trust
0.07%
Pension Fund
0.05%
Andere
6.62%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
5.31M
8.36%
-114.00K
-2.10%
Jun 30, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
T. Rowe Price Associates, Inc.
2.61M
4.12%
-360.60K
-12.13%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Citadel Advisors LLC
1.67M
2.64%
+195.41K
+13.22%
Jun 30, 2025
Westfield Capital Management Company, L.P.
1.26M
1.98%
-175.39K
-12.22%
Jun 30, 2025
Goldman Sachs & Company, Inc.
1.26M
1.98%
-19.32K
-1.52%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.16%
Goldman Sachs Future Health Care Equity ETF
0.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.12%
JPMorgan Healthcare Leaders ETF
0.03%
First Trust IPOX Europe Equity Opportunities ETF
0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Blue Chip Growth ETF
0.01%
Mehr Anzeigen
ALPS Medical Breakthroughs ETF
Anteil0.27%
Global X Guru Index ETF
Anteil0.16%
Goldman Sachs Future Health Care Equity ETF
Anteil0.12%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.12%
JPMorgan Healthcare Leaders ETF
Anteil0.03%
First Trust IPOX Europe Equity Opportunities ETF
Anteil0.02%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.01%
John Hancock Multifactor Small Cap ETF
Anteil0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
Anteil0.01%
Fidelity Blue Chip Growth ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
